A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Dactolisib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 18 Jan 2016 Results published in the BJU International
- 02 Jun 2015 Primary endpoint (Progression-free survival rate) has not been met, according to 2015 ASCO abstract.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.